Abstract
Objective To investigate the prevention and treatment of tumor recurrence with Sorafenib after orthotopic liver transplantation (OLT) for primary carcinoma of liver in rats. Methods Portal vein injection of Walker-256 cancer cells to establish models of metastasis and recurrence of liver after liver transplantation in rats. The rats were randomly divided into 4 groups(n＝16)：Control group (group A)； Sorafenib low-dose group (group B)； Sorafenib medium-dose group (group C)； Sorafenib high-dose group (group D)；moreover， a normal group (group E， n＝8). Eight rats of each group were chosen 20 days after operation to have observation of pathological changes in liver， which were made with hematoxylin-eosin sectioning (HE)；vascular endothelial growth factor (VEGF) and microvessel density (MVD) level of liver and lung tissues were detected by immunohistochemistry； bivariate correlation analysis of VEGF and MVD of liver were used to identify the relationship between them；survival time of remaining 8 rats from control group and experimental groups of Sorafenib were observed. Results There were no differences in tumor metastasis and recurrence among control group and Sorafenib experimental groups， for it could be found metastasis and recurrence in rat liver of each group， no cancer metastasis or recurrence found in lung of each group， however， Sorafenib experimental groups had signifcantly higher ratio of cancer cell apoptosis， lower ratio of necrosis of liver cells compared with control group； VEGF-positive ratio and MVD counts of liver in each experimental group were smaller than that of control group (P 0.05)；survival rate of medium-dose group and high-dose group were higher (P<0.05). Conclusions Sorafenib could inhibit synthesis of VEGF in tumor tissue， which could inhibit angiogenesis of tumor， then tumor growth， as well as invasion to normal liver cells were inhibited， and liver function damage was slighter， survival time were prolonged. As a result， there was a positive therapeutic effect of application of Sorafenib after orthotopic liver transplantation (OLT) for primary carcinoma of liver in rats.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
